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Abstract
Purpose Glioblastoma prognosis is poor. Treatment options are limited at progression. Surgery may benefit, but no quality 
guidelines exist to inform patient selection. We sought to describe variations in surgical management at progression, highlight 
where further evidence is needed, and build towards a consensus strategy.
Methods Current practice in selection of patients with progressive GBM for second surgery was surveyed online amongst 
specialists in the UK and Europe. We complemented this with an assessment of practice in a retrospective cohort study from 
six United Kingdom neurosurgical units. We used descriptive statistics to analyse the data.
Results 234 questionnaire responses were received. Maintaining or improving patient quality of life was key to decision 
making, with variation as to whether patient age, performance status or intended extent of resection was relevant. MGMT 
methylation status was not important. Half considered no minimum time after first surgery. 288 patients were reported in 
the cohort analysis. Median time to second surgery from first surgery 390 days. Median overall survival 815 days, with no 
association between time to second surgery and time to death (p = 0.874).
Conclusions This is the most wide-ranging examination of contemporaneous practice in management of GBM progres-
sion. Without evidence-based guidelines, the variation is unsurprising. We propose consensus guidelines for consideration, 
to reduce heterogeneity in decision making, support data collection and analysis of factors influencing outcomes, and to 
inform clinical trials to establish whether second surgery improves patient outcomes, or simply selects to patients already 
performing well.
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Introduction
Glioblastoma (GBM), the most common primary intrac-
ranial malignancy, represents 30% of all central nervous 
system tumours and has an incidence of 3.22 per 100,000 
individuals [1]. Standard care for newly diagnosed GBM 
is maximal safe resection, radiotherapy and concurrent 
and adjuvant temozolomide, and has changed little in 15 
years [2]. Despite treatment, prognosis is poor, with a 
median overall survival of 15 months. Tumour progres-
sion invariably occurs and may be referred to as recurrence 
[3]. Tumour progression nearly always develops within the 
margin of the original tumour [4]. At the time of tumour 
progression, clinicians may opt for best supportive care, 
further surgical excision, irradiation, chemotherapy or a 
combination of the above [5]. Survival following non-sur-
gical interventions varies widely [6]. Given the paucity of 
second line chemotherapy for the management of tumour 
progression, and the symptomatic consequences of tumour 
progression, there is an urgent need to determine the role 
of surgery [7].
Second surgical intervention was first proposed in 1968. 
It has been suggested that 25% of patients with progressive 
tumour may be eligible for consideration of second surgery 
[5]. However, the evidence base for this is poor. Studies that 
evaluated impact of second surgery have almost exclusively 
been based on single center retrospective cohorts, with 
no comparison to patients who do not get second surgery. 
Some of these studies reported greater overall survival and 
progression-free survival in select patients following sec-
ond surgery [8–10]. A meta-analysis and systematic review 
suggested second surgery in select patients conferred a sur-
vival advantage [11]. However, a subsequent meta-analysis 
recognized that the effect of the timing of second surgery 
on survival had been ignored [12]. They demonstrated that 
there was no survival benefit following reoperation once 
time to second surgery was controlled for.
There is a lack of evidence-based guidelines to support 
identification of which patients might benefit from second 
surgery. The 2018 National Institute of Clinical Excellence 
(NICE) guidelines (NG-99) [13] for brain tumours offer 
advice on management options (surgical and chemother-
apy) to consider in the treatment of disease progression, 
but no specific criteria by which to select patients to the 
various options. European Association of Neuro-oncology 
(EANO) guidelines simply suggest the option of second 
surgery should be explored, but without guidelines to sup-
port patient and clinician decision making [14]. Improved 
guidance for treatment selection would help patients and 
clinicians, reducing diversity in decision making, and 
would form a benchmark for the development of clinical 
trials and an improved evidence base.
The aim of this study was to determine areas of consensus 
and variation in practice, highlight where further evidence 
base needs to be developed, and build towards a consen-
sus management of GBM progression. This will serve as 
a benchmark for new guidelines and intervention studies. 
To develop a thorough understanding of current practice in 
selection of patients with progressive GBM for surgery, we 
surveyed surgeons in the UK and Europe. To further define 
the role of surgery, and to assess the extent to which actual 
practice mirrored that reported in the survey, we analysed 
outcomes following surgical management of tumour pro-
gression in six United Kingdom neurosurgical units.
Methods and materials
Questionnaire of practice
 A survey was designed using google docs (docs.google.
com) to elicit details of current management by the neuro-
oncology MDT (tumour board) of patients with GBM at the 
time of first treatment failure (Appendix 1).The survey was 
approved by the Society of British neurosurgeons (SBNS), 
the UK neuro-oncology community, and the European Asso-
ciation of Neurosurgeons (EANS). The survey was distrib-
uted by these organisations via email to their individual 
members, with online data collection. Respondents were 
asked to report the consensus management strategy for their 
local hospital MDT with regards to diagnosis of progression, 
decision making about proceeding to second surgery, and to 
ascertain what post-operative treatment was used. Data was 
analysed using descriptive statistics including measures of 
frequency such as count and percentage. Regional differ-
ences were outlined.
Retrospective surgical cohort analysis
Study design
This was a multi-centre retrospective study in a cohort of 
patients with GBM progression who underwent second 
surgery between January 2011 and January 2017, at 6 neu-
rosurgical units in the United Kingdom: Brighton, Edin-
burgh, Leeds, Newcastle, London, and Liverpool. Outcomes 
were assessed until October 31st, 2018.Local approval was 
obtained from each institution for anonymised data to be 
collected.
Participants & treatment characteristics
Patients eligible for this study: (i) had a histological diag-
nosis of GBM as determined by a consultant neuropatholo-
gist based on prevailing WHO classification (ii) received the 
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Stupp protocol for treatment of primary disease (surgical 
resection, concurrent and adjuvant temozolomide and 60 Gy 
of fractionated radiotherapy iii) underwent at least one fur-
ther instance of surgery for disease progression. Patients 
were identified from databases of surgical neuro-oncology 
patients maintained in each centre. Details including age at 
diagnosis and tumour location were recorded. Whether or 
not patients were offered adjuvant chemotherapy was also 
noted.
Outcomes
Overall survival was calculated from the date of histological 
diagnosis (i.e., date of first surgery) to date of death or last 
follow-up. Date of progression was defined from the date of 
second surgery.
Recorded adverse event data following all operations 
was collected and classified into (i) ‘neurological/pertain-
ing to surgery’ (ii) non-neurological/systemic (iii) infection. 
Patients in whom a pre-operative neurological deficit existed 
and did not change following surgery were not classed as 
having had a neurological complication.
Statistical methods
SPSS v.24 was used to perform statistical analyses. Bivari-
ate correlations were analysed using Pearson correlation. 
Threshold for significance was set as p-value ≤ 0.05.
Results
Questionnaire of practice
234 responses were received between January and March 
2018. There were 45 responses from the UK, 124 from 
Europe and 65 from the rest of the world. The international 
distribution of responders is shown in Fig. 1.
139 (59.4%) responses were from neuro-oncology sub-
specialty neurosurgeons, 82 (35.0%) from neurosurgeons 
without a declared subspecialty interest in neuro-oncology, 
12 (5.1%) responses were from clinical oncologists and 
1 response (0.4%) was from a neurologist. We combined 
the analysis of surgeons and other clinicians in the neuro-
oncology team to capture the spectrum of practice. The 
speciality of the clinician in charge of a patient at time 
of identification of progression could be a surgeon or 
oncologist.
We asked each respondent to record the number of cra-
niotomies for GBM performed annually in each hospital, 
and the number of second surgeries for tumour progres-
sion. Broadly the number of second surgeries increased in 
proportion to the number of primary surgeries (Table 1), 
and the trends were similar between UK, Europe, and the 
rest of the world. (Table 2).
Fig. 1  International distribution of respondents to online questionnaire
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Radiological surveillance, diagnostic criteria, 
and multidisciplinary review
Following completion of Stupp protocol treatment, 81.2% 
of responders reported performing radiological surveillance 
every 3-4 months in the first year. This decreased to 54.4% 
in the second year, with 37.6% instead opting for an imaging 
interval of 6 months. MRI was the most common modality 
used to diagnose progression and 94.4% respondents rely on 
identification of contrast enhancing disease, 44.0% on MR 
spectroscopy and 44.4% on MR perfusion. PET was also 
used for diagnosis by 26.1% of responders.
Interpretation of the significance of imaging changes 
often benefit from consideration of other patient factors 
and discussion within the multidisciplinary team. 68.4% of 
respondents presented every case of disease progression for 
MDT review (55.5% of respondents in the UK, 79.0% in 
Europe), 12.0% presented only those with progression local 
to the site of first surgery, and 7.3% only patients who had 
survived more than 9 months.
Patient and disease characteristics for consideration 
of surgery for progressive disease
Quality of  life More than 90% of respondents noted that 
maintaining and/or improving patient quality of life was a 
key determinant of the decision to proceed to surgery.
Age 44.9% of respondents did not consider that age influ-
enced decision making, whilst 27.8% of respondents thought 
age over 80 years made the patient unsuitable for second 
surgery, and 24.4% if the patient’s age was over 70 years.
Performance status When asked if there was a minimum 
KPS at the time of diagnosis of tumour progression for the 
patient to be considered for second surgery, 36.8% reported 
a minimum of 70, 23.5% a minimum of 80, 10.7% a mini-
mum of 90 and only 14.5% reporting that performance sta-
tus did not influence their decision making.
MGMT methylation status A quarter (25.2%) of respondents 
reported that their units did not routinely test MGMT tumour 
status from the first surgery. Of the remaining respondents, 
72.6% did not consider that MGMT methylations status 
should influence decision making.
Anticipated resection Over half (56.8%) of respondents 
would only consider surgery for tumour progression if a 
greater than 90% extent of resection (EoR) of the enhanc-
ing component was anticipated. Only 17.1% responded that 
the anticipated EoR did not influence their decision making.
Timing after first operation If tumour progression occurred 
whilst a patient was still being treated following the pri-
mary surgery, 45.7% of respondents thought this precluded 
further surgery. The time elapsed after first surgery to pro-
gression was thought to be important in decision making 
(62.8%), rather than the time after completion of chemo-
therapy. However, 45.3% did not consider there to be a mini-
mum duration after the first operation before consideration 
of second surgery for disease progression. There was no 
Table 1  Summary of the number of primary surgeries and second 
surgeries for glioblastoma according to questionnaire respondents
*Data point not answered by 6 responders




Number of surgeries for 
GBM progression per year 
(n)
< 5 5–10 > 10
> 100 48 0 7 41
51–100 84 7 26 51
21–50 70 27 27 16
1–20 26 21 3 2
Table 2  Number of institutions 
by volume of primary and 
second surgeries stratified 
for UK, Europe and out-with 
Europe
Number of GBM 
surgeries per year
UK: number of institu-
tions by primary and re-do 
surgeries per year (% of 
category)
Europe: number of institu-
tions by primary and re-do 
surgeries per year (% of 
category)
Out-with Europe: number 
of institutions by primary 
and re-do surgeries per year 
(% of category)
< 5 5–10 > 10 < 5 5–10 > 10 < 5 5–10 > 10
> 100 0 (0) 4 (20) 16 (80) 0 (0) 3 (14) 18 (86) 0 (0) 0 (0) 7 (100)
51–100 1 (8) 3 (23) 9 (69) 5 (9) 16 (29) 34 (62) 1 (6) 7 (44) 8 (50)
21–50 3 (50) 2 (33) 1 (17) 17 (45) 15 (39) 6 (16) 7 (27) 10 (38) 9 (35)
1–20 1 (100) 0 (0) 0 (0) 8 (80) 2 (20) 0 (0) 12 (80) 1 (7) 2 (13)
Journal of Neuro-Oncology 
1 3
consensus amongst the remainder of respondents. Once the 
decision for surgery for progressive disease has been made, 
78.6% of respondents thought surgery should then be priori-
tised on the next available list.
Second line chemotherapy and re‑irradiation
Following second surgery, 48.7% of respondents reported 
the multidisciplinary team would consider treatment with 
PCV, 41.9% with repeat temozolomide challenge if tumour 
methylated and 19.7% if unmethylated. 25.6% would con-
sider single agent lomustine. Other therapies under consider-
ation were bevacizumab (5.5%) or irinotecan (1.3%). 49.1% 
of respondents would consider re-irradiation, 20.9% would 
not, with the remainder being open to consider it in selected 
cases, especially in patient with longer survival from first 
surgery. 40.2% of respondents would consider second sur-
gery even if there were no further oncological treatment 
available. For these questions, respondents could complete 
more than one option.
Retrospective surgical cohort analysis
Patient demographics and tumour information
Across the 6 neurosurgical units, 288 patients were identified 
as having undergone second surgery for tumour progression 
during the study period. 24 patients (8.3%) had 3 operations. 
67 (23.2%) of patients were alive at the time of study.
The median overall survival was 815 days (27.2 months) 
(IQR 547–1296 days). The median age was 51 years (IQR 
44–60 years). The anatomical distribution of primary 
tumours was predominantly supratentorial, with 248 occu-
pying a single lobe (101 temporal, 85 frontal, 51 parietal, 
11 occipital, 1 thalamic, 1 tentorial, 1 intraventricular) and 
34 spread across 2 lobes. Multifocal tumours at diagnosis 
were identified in 3 patients. Tumour laterality was relatively 
even, with 165 right sided tumours and 122 left sided. Only 
1 patient in this cohort was documented as having bilateral 
disease.
Treatment characteristics for tumour progression
Median time to second surgery from first surgery was 390 
days (13 months) (IQR 241–686 days). The median time to 
death following second surgery was 316 days (10.5 months) 
(IQR 174–595 days). There was no association between time 
to second surgery and time to death following second surgery 
(Pearson correlation 0.009; p = 0.874). However, greater 
time to reoperation was positively correlated with greater 
overall survival (Pearson correlation = 0.655; p < 0.001). 192 
patients (81.7%) were offered further chemotherapy and 43 
(18.3%) were not; 53 patients had no data as to whether they 
were offered further chemotherapy.
Complications following surgery
For patients with data on adverse events following sec-
ond surgery, 54 (23.0%) experienced an adverse event; 35 
(14.9%) neurological and 7 (3%) non-neurological excluding 
infection. This compared to 42 patients (17.4%) having an 
adverse event recorded at first surgery; 11.6% had neurologi-
cal sequalae, 10 (4.1%) had non-neurological events exclud-
ing infection. Cranial infection rate for all patients at 1st, 
2nd and 3rd surgery was 2.1%, 5.1 and 12.5% respectively.
Discussion
Our questionnaire aimed to scope out a breadth of opinions 
and to identify what, if any, consensus exists. Such question-
naires provide only a snapshot of practice and there will be 
variations within countries, hospitals and even in the prac-
tice of individual clinicians that are not adequately deline-
ated with this strategy. However, our analysis has captured 
the variation that exists in the clinic about both patient selec-
tion and choice of surgical management, for people with pro-
gressive GBM. In the absence of existing robust evidence-
based guidelines, this is not surprising. A 2016 study of 
treatment algorithms for management of GBM progression 
in Switzerland identified considerable variability in the fac-
tors used for treatment decision making. ‘Fitness’, ‘resect-
ability’ and time from first surgery were used as criteria for 
determining re-treatment, including surgery.
The missing data in our cohort analysis reflects the rela-
tive low rate of surgery for tumour progression and the long 
period over which it was necessary to analyse data. It is 
possible that the centres we surveyed may not be representa-
tive of UK neurosurgery, but our findings are comparable to 
other published data. In our analysis, like most published 
data, the outcomes for patients who do not undergo second 
surgery, matched for clinical features, was not available. We 
know which patients selected for surgery perform best, but 
not whether a second operation provides an independent 
survival benefit.
As expected, a post-contrast MRI is the mainstay inves-
tigation leading to determination of disease progression. 
The UK NICE NG-99 [13] guidelines recommend imag-
ing every 3–6 months for the first 2 years after treatment, 
annually to year 4 and every 1-2 years thereafter. The ques-
tionnaire responses were consistent with this. The NG-99 
guidelines, which were published after the questionnaire 
was undertaken, are based on expert consensus rather than 
an evidence base. In both the NG-99 guidelines and the 
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questionnaire responses, frequency of imaging reduces as 
survival increases.
Advanced MRI techniques may increase diagnostic accu-
racy of disease progression [15], as compared to pseudo 
progression, but are difficult to interpret and the NG-99 
guideline committee recommended them only where extra 
information was likely to substantially alter treatment plans. 
Fewer than 50% of questionnaire respondents reported using 
MR spectroscopy or perfusion, and we don’t know whether 
that was for specific diagnostic difficulty, or as a routine 
methodology.
With uncertainty about diagnostic criteria for determining 
disease progression, the collective experience and opinions 
of the MDT are invaluable. NG-99 guidelines recommend 
that ‘if people having active monitoring show radiological 
or clinical disease progression, discuss this at a multidis-
ciplinary team meeting.’ In fact, only 68% of all patients 
with GBM progression are currently being discussed. This 
was lower in the UK (56%) compared to Europe (79%). The 
questionnaire responses indicated that in some cases MDT 
referral was only made if survival since diagnosis was more 
than 9 months or where disease progression was localised, 
neither of which variables has been well evidenced to be pre-
dictive of superior prognosis in response to further therapy.
In our retrospective cohort, overall median survival in 
the cohort study was 815 days, but without a comparator of 
non-operative patients, the true merits of surgery cannot be 
ascertained. The median interval between first and second 
surgery was 13 months, suggesting a preference to select 
better performing patients. Significantly, we found that the 
timing of reoperation was not associated with time-to-death 
following second surgery. A longer time to second surgery 
does not necessarily predict a commensurate longer time to 
death following second surgery, compared to a patient with 
a shorter time to their second surgery. The interpretation of 
this is that patients whose second surgery occurs later in the 
course of the disease are likely to survive longer overall, but 
not because of an additional survival benefit from the second 
surgery. This is consistent with the interpretation of Zhao 
et al. meta-analysis that demonstrated no survival benefit 
following second surgery once time to second surgery was 
controlled for [12]. Surprisingly, perhaps, almost two thirds 
of questionnaire respondents did not think that timing from 
first surgery mattered.
There may be merit in a minimum recommended time 
window from first surgery before consideration of further 
surgery, in the context of disease progression. Should this be 
time elapsed from the actual surgery, or from completion of 
chemotherapy? If the latter, would it be different for patients 
whose chemotherapy ended because of toxicity rather than 
disease progression? In the ongoing RESURGE study of 
surgery for progressive GBM, (https:// www. resur ge- trial. 
ch) eligibility includes first progression within 3 months of 
completion of radiotherapy, which broadly equates to only 
4-5 months post-surgery. That study has recruited fewer than 
40 patients in 5 years, underlining the challenges of recruit-
ing to a randomised trial. The UK cohort data, with median 
time to second surgery of 13 months, suggests a prefer-
ence amongst surgeons for a longer interval. Further, the 
questionnaire responses indicated that in some cases MDT 
referral was only made if survival since diagnosis was more 
than 9 months. Nine months post-surgery may be a useful 
cut-off for considering whether second surgery is likely to 
be beneficial. More evidence is needed thought to assess 
whether this is best for patients and since median progres-
sion free survival following standard care Stupp therapy is 
approximately 7 months [16], a shorter time interval may be 
appropriate to consider.
We cannot yet reliably predict who is most likely to ben-
efit from second surgery. Development of probabilistic mod-
els may support treatment decision making. Scoring systems 
proposed to date have been developed typically from small 
patient cohorts (approx. 100), from analysis of retrospective 
data sets of patients who have had surgery, without account-
ing for the outcomes of people who don’t have second sur-
gery. Factors in those models have included age, KPS, and 
tumour volume. More than 50% of questionnaire respond-
ents thought surgery was only appropriate if the expected 
extent of resection was greater than 90%. The RESURGE 
study specifies inclusion criteria to target patients eligible 
for maximum resection, with complete resection of the con-
trast enhancing tumour considered feasible and no involve-
ment of eloquent areas. Gross total resection (GTR) at first 
surgery has been consistently associated with improved 
patient outcomes, although the quality of the supporting 
evidence has been judged as moderate to low [17]. Support 
for the benefit of GTR second surgery has been reported 
[18, 19]. The DIRECTOR study compared TMZ regimens 
in GBM progression and a subgroup analysis of that study 
reported a significant increase in post-progression survival 
in patients having GTR [20], although those who had only 
partial resection tended to do worse than those without 
surgery (p = 0.52). This was a retrospective analysis of a 
selected study cohort, so the findings may not be generalis-
able. Moreover, predicted extent of tumour resection based 
on an individual patient’s imaging is contentious and can 
vary between surgeons, although scoring systems, artificial 
intelligence analysis and cloud-based systems for consensus 
gathering may help [21, 22]. Importantly, subtotal resec-
tion may still improve patient symptoms, and patients could 
potentially benefit from relatively modest debulking where 
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recent tumour tissue for molecular analysis is required for 
entry into a clinical trial.
Whatever the surgical goals, maintenance or improving 
of quality of life are paramount; 90% of our questionnaire 
respondents agreed. This needs to be discussed with patients 
and to inform the decision whether to proceed with sur-
gery. Success at maintaining and maximising quality of life 
depends in some part on the performance status of patients. 
40% of questionnaire respondents suggested patients should 
have a KPS of at least 70 (caring for self but not capable of 
normal activity or work) for consideration of further therapy 
on progression, whilst 30% thought KPS should be higher. 
Surgery itself must not harm patients, but it is possible that 
surgery improves performance status through relief of mass 
effect, so KPS of less than 70 will not necessarily be a bar-
rier to surgery. The incorporation of KPS score into a treat-
ment decision making tool must also acknowledge inter-rater 
variation in assessment of an individual patient.
When tumour progression occurs, assessment of a 
patient’s function may be influenced by whether they are 
taking steroid medication. Our questionnaire and cohort 
study did not investigate the role of steroids specifically. 
Steroid use at progression has been suggestive as predictive 
of poor outcome and in an analysis of data from the BRAIN 
study of Bevacizumab and irinotecan in GBM progression, 
patients who were able to reduce their steroid therapy whilst 
on treatment had a better outcome [23]. However, surgery 
and tumour debulking may reduce a patient’s need for ster-
oids, so functional dependence on dexamethasone may in 
fact be an indication for second surgery and predict good 
surgical outcome.
Alongside pre-operative performance status, age has also 
been reported as an important predictor of outcome at GBM 
progression [24, 25]. In that analysis of 333 phase I-II trial 
patients with GBM or malignant glioma, age less than 50 
was associated with better outcomes, although those stud-
ies were performed before the advent of current standard 
care therapies. Median age of patients undergoing surgery 
in our UK cohort was 51, consistent with other published 
cohorts of patients at time of second surgery [26]. This is 
much younger than the average age of GBM diagnosis gen-
erally, and discordant with questionnaire responders, 45% 
of whom thought age was not important, and 24% of whom 
thought age over 70 should be the cut off.
Molecular tumour characteristics are playing an increas-
ing role in the classification of gliomas, and treatment 
selection (ref; WHO, methylome). Brandes and colleagues 
reported a cohort of 270 patients who had second surgery for 
GBM progression, 44% of whom had methylation data [26]. 
Time from second surgery to death was significantly longer 
in people with methylated tumours; 13.8 v 10 months. Few 
of our questionnaire responders identified a role for MGMT 
methylation status in decision making, but this may change 
with increasing availability of the test. In our retrospective 
cohort study, 37.5% of patients who had repeat surgery had 
MGMT data available. Only 55% of these patients had pro-
moter methylation, suggesting that MGMT methylation was 
not an important determinant of the decision to proceed to 
surgery. The lack of MGMT data likely reflects that it was 
not routinely available in these centres during the period 
of study, rather than that there was a bias for it to be tested 
in certain patients. In future analyses molecular correlates 
of outcome require more interrogation, and we may need 
to consider reports that molecular status can change at 
progression.
Some commentators question whether second surgery for 
GBM progression has a role at all, citing a lack of additional 
benefit beyond re-irradiation and chemotherapy [27, 28]. 
That does not though preclude that some patients can benefit 
from surgery. There may also be additional benefits when 
surgical adjuncts (e.g. 5-Aminolaevulinic acid, intra-opera-
tive MRI) are used, which were not systematically employed 
in our cohort, and require further assessment. The potential 
benefit of surgery in disease progression may also be linked 
to the opportunity for a patient to access other therapies, 
whether standard care or as part of a clinical trial. Repeat tis-
sue sampling could be used to confirm marker expression for 
selection of targeted therapy, or development of the therapy 
itself, for example in vaccine trials [29]. Surgical debulking 
may support drug delivery or reduction of steroid dose, in 
turn improving efficacy of therapies such as immunotherapy 
[30]. 40% of responders to our questionnaire would consider 
repeat surgery even if no other treatments were available. 
Most commonly, however, PCV (49%) or re-challenge with 
TMZ if the tumour is methylated (42%) were preferred. This 
reflects the predominance of UK and European responders 
to our questionnaire. Single agent Lomustine at progression 
is most commonly used in North America and is the most 
common comparator for novel agents in randomised con-
trolled trials of progression [31]. Any surgical trial will need 
to account for or control these variations in practice. In our 
surgical cohort only 22% of patients for whom there was 
data received TMZ after surgery and 11% PCV. In Brandes’ 
analysis, 34% received Temozolomide, 27% nitrosurea based 
therapy and 20% other therapies, but there was no differ-
ence in survival according to whether chemotherapy was 
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delivered after second surgery, or what type of therapy was 
given [26].
Conclusions
Our analysis is the most wide-ranging examination of 
contemporaneous practice in management of people with 
GBM progression. Clinician decision making is hetero-
geneous, yet there are trends from our analysis that could 
inform consensus guidelines (Table 3) This analysis pro-
vides a framework for further discussion amongst the 
neuro-oncology community, and to identify the priority 
areas for further research. Guidelines will not mandate 
selection for or against surgery. Rather, by identifying 
these patient factors as important in predicting benefit 
from second surgery, we hope to reduce heterogeneity 
in decision making, contribute to development of a data 
set in which these associations can be more intimately 
probed, and inform design of clinical trials. The role of 
surgery, surgical adjuncts, and decision-making tools are 
best addressed in prospective clinical studies, because het-
erogeneity in routine care, and the relative infrequency 
of second surgery, contribute to difficulties in curating 
adequately detailed and powered retrospective data sets, 
with appropriate comparators.
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